The peripheral benzodiazepine receptor (Translocator protein 18kDa) in microglia: from pathology to imaging

Sriram Venneti1, Brian J Lopresti, Clayton A Wiley

  • 1Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

Progress in Neurobiology
|December 13, 2006
PubMed

Insights

Positron emission tomography (PET) with Translocator protein (18kDa) ligands can visualize activated microglia in the brain. This imaging approach may help track neuroinflammation and assess treatments for neurodegenerative diseases.

Area of Science:

  • Neuroscience
  • Immunology
  • Radiology

Background:

  • Microglia are key immune cells in the brain, implicated in neurodegenerative diseases like Alzheimer's.
  • Assessing microglial activation in vivo is crucial for understanding disease progression and treatment efficacy.

Purpose of the Study:

  • To explore the potential of positron emission tomography (PET) for imaging activated microglia in vivo.
  • To evaluate the use of Translocator protein (18kDa) (TSPO) ligands for visualizing microglial activation.

Main Methods:

  • Review of molecular characterization of TSPO and its regulation in activated microglia.
  • Examination of the rationale for using TSPO ligands in PET imaging.
  • Analysis of current evidence supporting TSPO-targeted PET for microglial imaging.

Main Results:

  • TSPO, formerly known as the peripheral benzodiazepine receptor (PBR), is a target for imaging activated microglia.
  • PET imaging using TSPO ligands shows promise for detecting neuroinflammation.

Conclusions:

  • TSPO-targeted PET imaging offers a potential method for assessing microglial activation in neurological disorders.
  • This technique could aid in monitoring disease progression and evaluating anti-neuroinflammatory therapies.

Related Concept Videos